The Psychedelic Medicine Of The Future
Psychological disorders such as depression, PTSD and OCD are difficult to treat. But there is a growing body of research suggesting that psychedelics may be the key for a successful treatment.
If you have been on our blog recently, then you may have noticed our growing trend of articles investigating the potential medical application of psychedelics. Many scientists are beginning to get behind this group of mind opening drugs. And what are they all thinking? That psychedelics are the future.
A Lifetime Of Potential Quashed By The War On Drugs
Go back to the 1940’s, when science was a bit less restrained when it came to drugs, and you will see that research into the medical applications of psychedelics skyrocketed when the hallucinogenic properties of LSD were discovered. There was great promise in the hearts of those investigating it, and implications were quickly found into the treatment of anxiety, PTSD, OCD and depression. Unfortunately, this research was quickly killed off by the War on Drugs, as blanket prohibition prevented any further research.
Just over 70 years on, and research is once again beginning to pick up, as it becomes evident that the War on Drugs has been a failure of epic proportions. Although research has only just started again, initial tests are going well, having found encouraging results. So far there has been research into four major psychedelics, these are LSD, Psilocybin (magic mushrooms), Ketamine and MDMA. It has been found that LSD could help with the treatment of anxiety and alcoholism; psilocybin with anxiety, PTSD and OCD; Ketamine with depression; and MDMA with PTSD and anxiety.
It all revolves around the treatment of psychological disorders, and ones that traditional pharmaceuticals struggle to treat. It comes as no surprise to those who have experience with the drugs - the curative potential of psychedelics is quickly discovered individually, and they have been used for thousands of years in both medical and entheogenic settings.
Looking To The Future Of Psychedelic Medicine
Although research is once again beginning to pick up, the backwards thinking spawned by the War on Drugs still lingers strong, and it continues to block and impede scientific leaps. Let’s look at the US as an example, where psychedelics are classed as Schedule I drugs. This is a classification of drugs that are seen as having a lot of potential for abuse, with no medical value present. Even though there is a lot of research to say otherwise, the DEA, who are responsible for drug law enforcement, refuse to acknowledge it, saying research is not extensive enough. The problem is, extensive research cannot take place as long as these drugs are schedule I, causing a catch 22 situation.
Of course it is important to bear in mind that the role of the DEA and other agencies of prohibition is not to seriously evaluate the potential of drugs in the first place. Economic interest and societal control are dictating the War on Drugs and the agencies are simply the executive arm of the system. The real evaluation of the success of the War on Drugs happens in someones bank account.
Fortunately, the US is losing influence and other countries are independently re-starting research into those substances. Perhaps surprisingly, research is beginning again within the UK. The UK, which is considered to be quite conservative when it comes to drug laws, has a very similar drug policy to the US, classifying psychedelics in the worst band of drugs. However, where they differ from the US is that research may take place with the written consent of the Home Office – allowing a catch 22 situation to be avoided. And the Home Office has given consent to a select few. Hopefully, this research will snowball in the way cannabis has, allowing for larger more extensive studies to take place in the future. Psychedelics hold the potential to improve the lives of many, and can be safely used in the correct settings. One day it might be widely accepted that they hold the key to true healing.